Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,099.51
(
-0.14%
)
US TECH 100
25,903.20
(
0.12%
)
Dow Jones
49,394.51
(
-0.11%
)
Brent Oil
94.18
(
3.87%
)
Bitcoin
75,678.02
(
-0.28%
)
News Focus
News Focus
Post# of 822210
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Locknload56

Send PM Follow Ignore
Followers 11
Posts 649
Boards Moderated 0
Alias Born 01/11/2022

Locknload56

Re: biosectinvestor post# 438431

Tuesday, 01/25/2022 2:17:03 PM

Tuesday, January 25, 2022 2:17:03 PM

Post# of 822210
NW Bio is currently conducting a 348-patient Phase III clinical trial of DCVax-L for newly diagnosed GBM patients, in both the US and Europe. In two early stage trials, prior to the current Phase III trial, patients with newly diagnosed GBM who were treated with DCVax-L showed median survival of 3 years. With current standard of care (surgery, radiation and chemotherapy) median survival for such patients is about 14.6 months.

How about German contacts? Anyone know anyone in the medical community there to get their opinion?
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News